Hoyoung Huh, M.D., Ph.D.

Hoyoung Huh, M.D., Ph.D., is the chairman of Geron Corporation, where he has also held executive chairman and director positions, and is on the board of directors for Addex Pharmaceuticals. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously the president, chief executive officer and chairman of BiPar Sciences Inc., which was acquired by Sanofi-Aventis in 2009. Prior to that, he served as the chairman of Epizyme Inc., chief operating officer and board member of Nektar Therapeutics and board member of Facet Biotech, which was acquired by Abbott Laboratories in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in genetics and cell biology from Cornell University/Sloan-Kettering Institute.